Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Moodys
Boehringer Ingelheim
McKesson
Merck

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207931

See Plans and Pricing

« Back to Dashboard

NDA 207931 describes TECHNIVIE, which is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the TECHNIVIE profile page.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
Summary for 207931
Tradename:TECHNIVIE
Applicant:Abbvie Inc
Ingredient:ombitasvir; paritaprevir; ritonavir
Patents:10
Generic Entry Opportunity Date for 207931
Generic Entry Date for 207931*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 207931
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931 NDA AbbVie Inc. 0074-3082 0074-3082-28 4 CARTON in 1 CARTON (0074-3082-28) > 7 DOSE PACK in 1 CARTON > 1 KIT in 1 DOSE PACK

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength12.5MG;75MG;50MG
Approval Date:Jul 24, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:Jan 19, 2020Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:May 10, 2021Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 207931

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015   Start Trial   Start Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Johnson and Johnson
McKinsey
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.